Molecular Profile | NPM1-ALK ALK C1156F ALK D1203N |
Therapy | ASP3026 |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
Create By | c-seddy |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | NPM1-ALK ALK C1156F ALK D1203N | Advanced Solid Tumor | resistant | ASP3026 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034). | 25749034 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(25749034) | NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. | Full reference... |